 FOSTER CITY, Calif., Dec. 20, 2022 GLOBE NEWSWIRE Terns Pharmaceuticals, Inc. Terns or the Company Nasdaq: TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis NASH, today announced the pricing of its underwritten public offering of 10,350,000 shares of its common ... The post Terns Announces Pricing of 75 Million Public Offering appear... 